Biolegend, 100751, Brilliant Violet 510™ anti-mouse CD8a Antibody, 125microl

CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.
125microl
Verified Reactivity: Mouse
Antibody Type: Monoclonal
Host Species: Rat
Immunogen: Mouse thymus or spleen
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation: The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 510™ under optimal conditions.
Concentration: µg sizes: 0.2 mg/mLµL sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: FC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the µg size, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. For immunofluorescent staining using the µl size, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.Brilliant Violet 510™ excites at 405 nm and emits at 510 nm. The bandpass filter 510/50 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 510™ is a trademark of Sirigen Group Ltd.Learn more about Brilliant Violet™. This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser: Violet Laser (405 nm)
Application Notes: Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).
Application References(PubMed link indicates BioLegend citation): Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP) Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete) Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP) Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block) Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC) Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC) Shih FF, et al. 2006. J. Immunol. 176:3438. (FC) Kamimura D, et al. 2006. J. Immunol. 177:306. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete) Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed Lee CH, et al. 2009. Clin. Cancer Res. PubMed Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed Guo Y, et al. 2008. Blood 112:480. PubMed Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed Kenna TJ, et al. 2008. Blood 111:2091. PubMed Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed Medyouf H, et al. 2010. Blood 115:1175. PubMed Riedl P, et al. 2009. J. Immunol. 183:370. PubMed Apte SH, et al. 2010. J. Immunol. 185:998. PubMed Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed Cui L, et al. 2015. J Control Release. 206:220. PubMed Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations: Saha D et al. 2017. Cancer cell. 32(2):253-267 . PubMed Li SX, et al. 2019. PLoS Pathog. 15:e1007611. PubMed Wu R, et al. 2022. Nat Immunol. 23:1536. PubMed Li Y, et al. 2023. Adv Mater. 35:e2208923. PubMed Giampaolo S, et al. 2023. iScience. 26:106234. PubMed Byrne PO, et al. 2023. Nat Commun. 14:1494. PubMed del Rio ML, et al. 2023. Front Immunol. 14:1113858. PubMed Seclì L, et al. 2023. J Immunother Cancer. 11:. PubMed Lee K, et al. 2023. JCI Insight. 8:. PubMed Wang X, et al. 2023. NPJ Vaccines. 8:76. PubMed Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed Collin R, et al. 2020. J Immunol. 205:133. PubMed Koenig A, et al. 2022. Front Immunol. 12:791100. PubMed Dolfi B, et al. 2022. Cell Rep. 39:110949. PubMed Liu H, et al. 2022. Cell Rep Med. 3:100660. PubMed Kang IH, et al. 2022. iScience. 25:104818. PubMed Miró L, et al. 2022. Cancers (Basel). 14: . PubMed Schepers M, et al. 2023. Brain Behav Immun. 109:1. PubMed Jin SM, et al. 2023. Nat Nanotechnol. :. PubMed Kemna J, et al. 2023. Nat Immunol. 24:414. PubMed Scherer S, et al. 2023. Nat Immunol. 24:501. PubMed Jiang L, et al. 2021. Nano Today. 36:. PubMed Vesin B, et al. 2022. Mol Ther. 30:2984. PubMed Reticker-Flynn NE, et al. 2022. Cell. 185:1924. PubMed Kim S, et al. 2020. Immunity. 53(4):759-774.e9. PubMed Zhang LJ, et al. 2019. Immunity. 50:121. PubMed Wilfahrt D, et al. 2021. Elife. 10:. PubMed Otano I, et al. 2021. Nat Commun. 12:7296. PubMed Zhou J, et al. 2021. Int J Med Sci. 18:3516. PubMed Lino AC et al. 2018. Immunity. 49(1):120-133 . PubMed Wang D, et al. 2018. Immunity. 48:659. PubMed Baldwin SL, et al. 2021. PLoS One. 16:e0247990. PubMed Stegelmeier AA, et al. 2022. Biomedicines. 10:. PubMed Steubing RD, et al. 2022. Brain Behav Immun Health. 24:100493. PubMed Wang C, et al. 2015. Sci Rep. 5: 14124. PubMed Larsen SE, et al. 2021. Sci Rep. 11:9040. PubMed Chen J, et al. 2022. J Nanobiotechnology. 20:283. PubMed Rodriguez-Ruiz M, et al. 2016. Cancer Res . 76: 5994 - 6005. PubMed Fuster JJ, et al. 2020. Cell Rep. 33:108326. PubMed Si Y, et al. 2020. Sci Adv. 6:eaba0995. PubMed Matsuoka S, et al. 2019. Haematologica. 105:226. PubMed Gajdasik DW, et al. 2020. Nat Commun. 2.834027778. PubMed Jenkins RW, et al. 2018. Cancer Discov. 8:196. PubMed Müller M, et al. 2021. Nat Commun. 12:7036. PubMed Tuttle KD, et al. 2020. Cell Rep. 33:108407. PubMed Dikiy S, et al. 2021. Immunity. 54(5):931-946.e11. PubMed Flommersfeld S, et al. 2021. Immunity. :. PubMed Aegerter H, et al. 2020. Nat Immunol. 0.975694444. PubMed Lissner MM, et al. 2020. Elife. 9:00. PubMed Hiramoto T, et al. 2018. Mol Ther. 26:1255. PubMed Yang L, et al. 2021. Cell Death Differ. 28:2616. PubMed Bogie JF, et al. 2020. Ther Adv Chronic Dis. 11:2040622320947378. PubMed Koivisto CS, et al. 2020. Neoplasia. 1.252777778. PubMed Dietmar Herndler‐Brandstetter et al. 2018. Immunity. 48(4):716-729 . PubMed Telford W, et al. 2017. Cytometry A. 91:314. PubMed Leylek R, et al. 2019. Cell Rep. 29:3736. PubMed Yu X, et al. 2020. Cancer Cell. 37(6):850-866. PubMed Friedman DJ, et al. 2021. Cancer Immunol Res. 9:952. PubMed Pitsch J, et al. 2021. Ann Neurol. 89:666. PubMed Knizkova D, et al. 2022. Nat Immunol. 23:1644. PubMed Mulas F, et al. 2020. Cell Mol Immunol. . PubMed Ringel AE, et al. 2020. Cell. 183(7):1848-1866.e26. PubMed Liu CY, et al. 2020. Cell Rep. 33:108275. PubMed Jing Y, et al. 2020. Sci Adv. 6:eaax9455. PubMed Bradley KC, et al. 2019. Cell Rep. 28:245. PubMed Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed Cosentino K, et al. 2022. Mol Cell. 82:933. PubMed Vogel A, et al. 2022. STAR Protoc. 3:101653. PubMed Ni J, et al. 2020. Immunity. 52(6):1075-1087.e8. PubMed Kyburz A, et al. 2019. J Allergy Clin Immunol. 143:1496. PubMed Moore MJ et al. 2018. eLife. 7 pii: e33057. PubMed Puigdelloses M, et al. 2021. J Immunother Cancer. 9:. PubMed Ma X, et al. 2020. Immunity. 53:1315. PubMed van Vloten JP, et al. 2019. Mol Ther Methods Clin Dev. 13:154. PubMed Kyburz A, et al. 2017. Clin Exp Allergy. 47:1331. PubMed Cosway EJ, et al. 2017. J Exp Med. 214:3183. PubMed Ge C, et al. 2020. Cell Reports. 29(13):4236-4244.e3.. PubMed Souza SP, et al. 2021. PLoS Pathog. 17:e1010081. PubMed Loo CS, et al. 2020. Immunity. 53:143. PubMed Zhu D, et al. 2017. Stem Cell Res Ther. 0.511805556. PubMed Fowler AM et al. 2018. Cell host & microbe. 24(5):743-750 . PubMed Varikuti S, et al. 2020. Br J Cancer. 122:1005. PubMed Jiang L, et al. 2020. Cell. 183(5):1219-1233.e18. PubMed Soukup K, et al. 2017. Sci Rep. 10.1038/s41598-017-12208-7. PubMed Urata S, et al. 2018. PLoS Pathog. 14:e1007172. PubMed Mao W, et al. 2019. J Immunother Cancer. 0.484027778. PubMed Wang D, et al. 2022. EMBO Rep. 23:e53691. PubMed Tsai HI, et al. 2021. EMBO Mol Med. 13:e12834. PubMed Mairhofer D, et al. 2015. J Invest Dermatol. 135: 2785-93. PubMed Chen Y, et al. 2021. Nat Immunol. 22:996. PubMed Kim MY, et al. 2022. Nat Commun. 13:3296. PubMed Vogel A, et al. 2022. Cell Rep. 38:110420. PubMed Di Pilato M, et al. 2021. Cell. 184(17):4512-4530.e22. PubMed Bommareddy PK, et al. 2019. J Biol Methods. 6:2. PubMed Schaftenaar FH, et al. 2019. Sci Rep. 9:17391. PubMed Sun Y, et al. 2020. J Immunol. 205:2649. PubMed Wang R, et al. 2022. J Immunother Cancer. 10:. PubMed Tzeng TT, et al. 2022. NPJ Vaccines. 7:60. PubMed Teijeira á, et al. 2020. Immunity. 52(5):856-871. PubMed Tao Z, et al. 2022. Cells. 11:. PubMed McAusland TM, et al. 2021. Mol Ther Oncolytics. 20:306. PubMed Wang T, et al. 2015. Proc Natl Acad Sci U S A. 112:440. PubMed Wang X, et al. 2021. Immunity. 54(6):1123-1136.e8. PubMed Rappe JCF, et al. 2021. J Exp Med. 218:. PubMed Du Z, et al. 2020. J Allergy Clin Immunol. . PubMed Jiang W, et al. 2021. Cell Rep. 37:110112. PubMed Zhang L, et al. 2021. Mol Ther. 29:744. PubMed Liu Y, et al. 2021. Nat Commun. 12:6831. PubMed
RRID: AB_2561389 (BioLegend Cat. No. 100751) AB_2563057 (BioLegend Cat. No. 100752)
Structure: Ig superfamily, CD8α chain, 34 kD
Distribution: Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells
Function: Co-receptor for TCR
Ligand/Receptor: MHC class I molecule
Antigen References: 1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press. 2. Zamoyska R. 1994. Immunity 1:243. 3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.
Gene ID: 12525
UniProt: View information about CD8alpha on UniProt.org
Clone: 53-6.7
Regulatory Status: RUO
Other Names: T8, Lyt2, Ly-2
Isotype: Rat IgG2a, κ